Priyanka Iyer, M.B.B.S
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Associate Program Director, Oncologic Endocrinology fellowship program, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Armed Forces Medical College, Pune Maharashtra University of Health Sciences, Pune, IN, Medicine, MBBS |
Postgraduate Training
| 2017-2018 | Research Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2017 | Clinical Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2015 | Chief Resident, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
| 2012-2014 | Clinical Residency, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
| 2011-2012 | Clinical Internship, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
Licenses & Certifications
| 2022 | Texas Medical Board License |
| 2018 | Oregon Medical License |
| 2017 | American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism |
| 2014 | American Board of Internal Medicine |
Experience & Service
Other Professional Positions
Endocrinologist, PeaceHealth Medical Group, Eugene, OR, 2018 - 2022
Extramural Institutional Committee Activities
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, IOTOX Working group Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Oncologic Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Anaplastic Thyroid Cancer (ATC) Planning Clinic, The University of Texas MD Anderson Cancer Center, 2016 - Present
Honors & Awards
| 2018 | First Prize, Clinical Research poster session, Division of Internal Medicine Research Retreat, The University of Texas MD Anderson Cancer Center |
| 2018 | First Prize, Clinical Research poster session, Research Symposium,, Baylor College of Medicine |
| 2018 | Helmsley Charitable Trust Abstract Awards in Type 1 Diabetes, Endocrine Society |
| 2018 | Young Investigator Award, Women in Endocrinology, Endocrine Society |
| 2017 | Dr. Lawrence CB Chan Award for Research Excellence, Baylor College of Medicine |
| 2017 | Finalist, DOIM Research Retreat Poster Session, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2017 | First Prize, Trainee Poster Contest in the Clinical Research Category, American Thyroid Association (ATA) |
| 2016 | The Leona M. and Harry B. Helmsley Charitable Trust Abstract Travel Support Award, Endocrine Society |
| 2014 | Finalist (Second Place), Maryland ACP Diagnostic Dilemma Competition |
| 2011 - 2014 | Outstanding Performance Award in the Area of Ambulatory Medicine, Sinai Hospital |
| 2011 - 2013 | Excellence in Professionalism and Humanism Award, Sinai Hospital |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Advanced Thyroid Cancer- Thinking Outside the Box!. Invited. ThyCa. Houston, Texas, US.
- 2024. ABCs of Thyroid cancer, Advanced Thyroid Cancer. Invited. ThyCa. Houston, Texas, US.
- 2023. ABCs of Thyroid Cancer. Invited. ThyCa. Houston, Texas, US.
- 2022. IOTOX Endocrine Toxicities. Invited. National IOTOX Clinical Educational symposium. Houston, TX, US.
- 2017. Molecular targeted therapy in anaplastic thyroid carcinoma. Conference. Molecular targeted therapy in anaplastic thyroid carcinoma. Houston, TX, US.
Regional Presentations
- 2025. Navigating Complex Cases of Thyroid Cancer. Invited. Texas Endocrinology Association (TXEA). San Antonio, Texas, US.
National Presentations
- 2018. Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: A Cancer Center Experience. Conference. Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: A Cancer Center Experience. Chicago, IL, US.
- 2016. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. Conference. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. Denver, CO, US.
International Presentations
- 2024. GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with Testing and treatment. Poster. ESMO Asia Congress 2024, SG.
Formal Peers
- 2023. FY23 IOTOX Educational Lecture Series. Visiting, US.
- 2023. Management of Anaplastic Thyroid Carcinoma. Visiting, US.
- 2022. FY23 IOTOX Educational Lecture Series. Visiting, US.
- 2022. Grand Rounds. Visiting, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | Novel treatment approach to cancer immunotherapy induced diabetes |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 |
| Title: | IMRT followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II trial adjuvant Pembrolizumab after IMRT in ATC |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Collaborator |
| Date: | 2021 |
| Title: | Pembrolizumab in combination with dabrafenib and trametinib as a neoadjuvant strategy prior to surgery in BRAF-mutated anaplastic thyroid cancer |
| Funding Source: | National Institutes of Health, MERCK |
| Role: | Collaborator |
| Date: | 2021 |
| Title: | Neoadjuvant/Adjuvant Treatment with Selpercatinib in RET-Altered Thyroid Cancers |
| Funding Source: | Lilly |
| Role: | Collaborator |
| Date: | 2019 |
| Title: | Lenvatinib in combination with pembrolizumab for stage IVB locally advanced and unresectable or stage IVC metastatic anaplastic thyroid cancer |
| Funding Source: | Merck & Co |
| Role: | Collaborator |
| Date: | 2019 |
| Title: | Biomarkers in thyroid cancer associated with aggressive behavior, treatment response, and survival outcomes |
| Funding Source: | National Institute of Health |
| Role: | Collaborator |
| Date: | 2017 |
| Title: | Atezolizumab Combinations with Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas |
| Funding Source: | Genentech, MDACC |
| Role: | Co-PI |
| Date: | 2017 - 2018 |
| Title: | Circulating BRAF V600E cell free DNA (cfDNA) as a biomarker of response in the management of Anaplastic Thyroid Carcinoma |
| Funding Source: | Endocrine Fellows Foundation |
| Role: | PI |
| Date: | 2015 |
| Title: | Clinical Outcomes of Patients with Poorly Differentiated Thyroid Carcinoma |
| Funding Source: | N/A |
| Role: | Collaborator |
Selected Publications
Book Chapters
- Iyer, PC, Srour, S, Hofmann, M, Cabanillas, ME. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer, 307-324, 2024.
- Iyer PC, Abadilla K, Dobs A. Medical disorders and complications of alcohol and other drugs, pain and addiction. In: Textbook of Addiction Treatment: International Perspectives. Springer Milan Heidelberg New York Dordrecht London, 1811-1830, 2015.
Patient Reviews
CV information above last modified November 18, 2025